Glycogen phosphorylase inhibitors: a patent review (2008 – 2012)

Abstract

Introduction: Glycogen phosphorylase (GP) is the enzyme responsible for the synthesis of glucose-1-phosphate, the source of energy for muscles and the rest of the body. The binding of different ligands in catalytic or allosteric sites assures activation and deactivation of the enzyme. A description of the regulation mechanism and the implications in glycogen metabolism are given.

Areas covered: Deregulation of GP has been observed in diseases such as diabetes mellitus or cancers. Therefore, it appears as an attractive therapeutic target for the treatment of such pathologies. Numbers of inhibitors have been published in academic literature or patented in the last two decades. This review presents the main patent claims published between 2008 and 2012.

Expert opinion: Good inhibitors with interesting IC₅₀ and in vivo results are presented. However, such therapeutic strategy raises questions and some answers are proposed to bring new insights in the field.

Keywords::

• allosteric inhibitors
• cancer
• glycogen phosphorylase
• patents
• regulation
• type 2 diabetes

Notes

This box summarizes key points contained in the article.